DOCSLIB.ORG

Narcotic Drugs Stupefiants Estupefacientes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

E/INCB/1993/21Supp.6 INTERNATIONAL NARCOTICS CONTROL BOARD - VIENNA SUPPLEMENT No. 6 TO NARCOTIC DRUGS ESTIMATED WORLD REQUIREMENTS FOR 1994 STATISTICS FOR 1992 ESTIMATES UPDATED AS OF 30 JUNE 1994 ORGANE INTERNATIONAL DE CONTROLE DES STUPEFIANTS - VIENNE SUPPLEMENT N° 6 A r STUPEFIANTS EVALUATIONS DES BESOINS DU MONDE POUR 1994 STATISTIQUES POUR 1992 EVALUATIONS A JOUR AU 30 JUlN 1994 JUNTA INTERNACIONAL DE FISCALlZACION DE ESTUPEFACIENTES - VIENA SUPLEMENTO N.o 6 A ESTUPEFACIENTES PREVISIONES DE LAS NECESIDADES MUNDIALES PARA 1994 ESTADfsTICAS PARA 1992 PREVISIONES ACTUALlZADAS AL 30 DE JUNIO DE 1994 ~If..~~ ~ ~-tR UNITED NATIONS - NATIONS UNIES - NACIONES UNIDAS 1994 The updating of Table A is carried out by means of 12 monthly supplements. In order to facilitate the task of the exporting countries, the 12 supplements now report all the totals of the estimates and not only the amended data. In this way, each supplement cancels and replaces the published table in its entirety. In order to accelerate the transmission of the supplements to the competent national authorities, the 12 supplements will appear in English. Reading of these 12 supplements in French and Spanish may be facilitated by consulting the indexes of countries and territories and of narcotic drugs appearing in the annual publication. La mise El jour du tableau A s'effectue au moyen de douze supplements mensuels. Afin de faciliter la tache des pays exportateurs, les douze supplements contiennent tous les totaux des evaluations et non pas seulement les chiffres qui ont ete modifies. De celte maniere, chaque supplement annule et remplace entierement le tableau publie. En vue d'accelerer la communication des supplements aux autorites competentes, les douze supplements seront publies en anglais. La lecture en franr;:ais et en espagnol de ces douze supplements pourra €ltre facilitee par la consultation des index des pays et territoires et des stupefiants de la publication annuelle. La actualizacion del cuadro A se efectua mediante doce suplementos mensuales. Para facilitar la tarea de los paises exportadores, en esos doce suplementos tiguran todos los totales de las previsiones y no solo las citras que se han modificado. De este modo, cada suplemento anula y sustituye por completo el cuadro publicado. Con el tin de acelerar la comunicacion de los suplementos alas autoridades nacionales competentes, los doce suplementos aparecen en ingles. La lectura de estos doce suplementos en espafiol y en trances se vera facilitada si se consultan los indices de paises y territorios que figuran en la publicacion anual. E/INCB/1993/2/Supp.6 30.6.1994 UNITED NATIONS PUBLICATION ISSN 1013-8250 ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN 1994 TOTAL OF ESTIMATES IN GRAMS FENTANYL 15 ~.FGHANISTAN* MORPHINE 30 PETHIDINE 365 CODEINE 189 540 ETHYLMORPHINE 1 060 ANGUILLA* ?ENTANYL 1 :1ETHADONE 50 COCAINE 2 :':ORPHINE 500 CODEINE 3 OPIUM 8 000 DIHYDROCODEINE 11 ?ETHIDINE 10 000 FENTANYL 1 MORPHINE 3 ;'.LB.llliIA * PETHIDINE 54 6-[.lONOACETYLMORPHINE 1 ANTIGUA AND BARBUDA* c.l\NNABIS 10 C.l\NNABIS RESIN 5 6-MONOACETYLMORPHINE 1 COCAINE 375 CANNABIS 5 CO:JEINE 30 000 CANNABIS RESIN 3 ETHYLMORPHINE 375 COCAINE 18 FENTANYL 6 CODEINE 450 HEROIN 1 FENTANYL 2 :·lETHADONE 1 HEROIN 1 !·lORPHINE 5 MORPHINE 9 OPIUM 5 OPIUM 1 PETHIDINE 3 750 PETHIDINE 450 THEBAINE 1 ARGENTINA .::.LGERIA 3-MONOACETYLMORPHINE 1 6-HONOACETYLMORPH INE 1 6-MONOACETYLMORPHINE 1 .::.LFENTANIL 30 ACETYLCODEINE 1 CANNABIS 10 ALFENTANIL 200 CANNABIS RESIN 5 CANNABIS 10 , COCAINE 1 CANNABIS RESIN .L CODEINE 160 000 COCA LEAF 100 DEXTROMORAM I DE 890 COCAINE 2 COO ?ENTANYL 36 CODEINE 260 COO HEROIN 1 CONC. OF POPPY STRAW 500 COO ;·lORPHINE 350 DEXTROPROPOXYPHENE 2000 000 OPIm~ 10 DIHYDROCODEINE 80 C' 00 PETHIDINE 3 000 DIPHENOXYLATE 5 000 PHENOPERIDINE 350 ECGONINE 1 PHOLCODINE 180 000 ECGONINE BENZOYLESTER 1 THEBAINE 1 ECGONINE METHYLESTER 1 ETHYLMORPHINE 80 000 .1..NDORRA FENTANYL 600 HEROIN 10 .::.LFENTANIL 4 HYDROCODONE 60 000 COCi'IINE 15 METHADONE 10 CODEINE 20 MORPHINE 430 000 ?ENTANYL 2 OPIUM 10 000 !·1ETHADONE 5 OXYCODONE 10 000 r·!ORPHINE 250 PETHIDINE 70 000 OPIUJ~ 10 PHOLCODINE 61 000 PETHIDINE 200 SUFENTANIL 200 PHENOPERIDINE 7 THEBAINE 140 000 .::11GOLA* ARMENIA CODEINE 7 620 See RUSSIAN FEDERATION DEXTROr~ORA.r~ I DE 1 PAGE 2 TOTAL OF ESTIMATES IN GRAM\ ARUBA ECGONINE METHYLESTER 1 ------------------------ ETHYLMORPHINE 1 2DC BEZITRAHIDE 2 ETORPHINE COCAINE 22 FENTANYL 20C CODEINE 99 HYDROMORPHONE 10C DEXTROMORAMIDE 1 METHADONE 55 000 DEXTROPROPOXYPHENE 4 MORPHINE 140 000 FENTANYL 1 MORPHINE-3-GLUCURONIDE 10 HYDROCODONE 51 MORPHINE-6-GLUCURONIDE 300 METHADONE 1 NICOCODINE 16 500 MORPHINE 375 NICOMORPHINE 4 600 OPIUM 458 OPIUM 12 000 OXYCODONE 60 PETHIDINE 50 000 PETHIDINE 1 170 PIRITRAMIDE 7 000 SUFENTANIL 110 ASCENSION ISLAND THEBAINE 1 000 ------------------------ FENTANYL 6 AZERBAIJAN MORPHINE 13 ------------------------ PETHIDINE 25 CODEINE 1 800 ETHYLMORPHINE 2 000 AUSTRALIA FENTANYL ------------------------ OPIUM 842 ALFENTANIL la PIRITRAMIDE 150 ANILERIDINE 170 000 TRIMEPERIDINE 2 050 CANNABIS 50 COCAINE 15 500 BAHAMAS CODEINE 9150 000 ------------------------ CONC. OF POPPY STRAW 65000 000 CANNABIS 35 DEXTROMORAMIDE 3 000 CANNABIS RESIN 25 DEXTROPROPOXYPHENE 2200 000 COCA LEAF 50 DIFENOXIN la COCAINE 60 DIHYDROCODEINE 600 000 CODEINE 3 000 DIHYDROMORPHINE 5 DEXTROPROPOXYPHENE 5 000 DIPHENOXYLATE 110 000 ETHYLMORPHINE 10 ETHYLMORPHINE 3 150 FENTANYL 2 ETORPHINE la HYDROCODONE 300 FENTANYL 600 MORPHINE 600 HEROIN la OPIUM 20 HYDROCODONE 1 000 OXYCODONE 900 HYDROMORPHONE la PETHIDINE 10 000 METHADONE 300 000 METHADONE-INTERMEDIATE 20 000 BAHRAIN MORPHINE 10405 000 ------------------------ MORPHINE-3-B-D-GLUCURONIDE 5 COCAINE 100 MORPHINE-6-B-D-GLUCURONIDE 5 CODEINE 500 NORMETHADONE 20 ETORPHINE 3 OPIUM 31 500 FENTANYL 6 OXYCODONE 675 000 METHADONE 5 OXYMORPHONE 5 MORPHINE 503 PETHIDINE 750 000 PETHIDINE 5 363 PETHIDINE INT. -A 250 000 PHENOPERIDINE 3 PHENOPERIDINE 100 PHOLCODINE 302 000 BANGLADESH* SUFENTANIL 100 ------------------------ THEBAINE 1050 000 CODEINE 7 988 FENTANYL 10 AUSTRIA PETHIDINE 113 535 ------------------------ PHOLCODINE 105 000 ALFENTANIL 300 COCAINE 2 000 BARBADOS CODEINE 195 000 ------------------------ DEXTROPROPOXYPHENE 180 000 COCAINE 243 DIHYDROCODEINE 150 000 CODEINE 23 266 ECGONINE 1 DIHYDROCODEINE 173 ECGONINE BENZOYLESTER 1 FENTANYL 1 HYDROCODONE 110 METHADONE 10 TOTAL OF ESTIMATES IN GRAMS PAGE 3 :·IORPHINE 520 MORPHINE 25 OXYCODONE 94 PETHIDINE 1 500 PETHIDINE 4 731 SUFENTANIL 1 BENIN BELARUS CODEINE 1 000 ECGONINE 1 See RUSSIAN FEDERATION ECGONINE BENZOYLESTER 1 ECGONINE METHYLESTER 1 BELGIUM FENTANYL 1 MORPHINE 10 6-MONOACETYLMORPH INE 2 PETHIDINE 1 000 .:'CETYLD IHYDROCODE INE 36 514 .=lliFENTANIL 40 166 BERMUDA BEZITRAMIDE 5 181 :ANNABIS 98 ALFENTANIL 5 :OCA LEAF 57 417 COCAINE 200 COCAINE 133 708 CODEINE 2 000 CODEINE 3312 000 DEXTROMORAMIDE 15 CONC. OF POppy STRAW 2600 000 DIHYDROCODEINE 1 000 DEXTROMORAMIDE 45 000 ETORPHINE 5 DEXTROPROPOXYPHENE 396 021 FENTANYL 1 DIETHYLTHIAMBUTENE 20 METHADONE 400 DIFENOXIN 827 MORPHINE 1 500 DIHYDROCODE INE 114 883 OPIUM 100 DIPHENOXYLATE 500 000 OXYCODONE 200 DIPIPANONE 60 OXYMORPHONE 1 ECGONINE BENZOYLESTER 6 PETHIDINE 3 000 ECGONINE METHYLESTER 6 ETHYLMORPH INE 245 396 BHUTAN ETORPHINE 20 ETOXERIDINE 20 CODEINE 3 700 ICENTANYL 15 000 DEXTROPROPOXYPHENE 2 250 HEROIN 1 958 MORPHINE 75 HYDROCODONE 42 403 PETHIDINE 435 HYDROMORPHONE 806 ISOMETHADONE 20 BOLIVIA LEVOMORAMIDE 910 LEVORPHANOL 20 ALFENTANIL 10 !·lETHADONE 108 794 COCAINE 25 :'lORPHINE 3282 000 CODEINE 28 000 NICOMORPHINE 20 DEXTROPROPOXYPHENE 190 000 NORCODEINE 2 DIHYDROCODEINE 5 000 HORMETHADONE 200 FENTANYL 30 NORMORPHINE 2 HYDROCODONE 5 000 OPIUM 227 639 METHADONE 500 OXYCODONE 3 842 PETHIDINE 6 000 PETHIDINE 55 798 PETHIDINE INT. -B 20 BOSNIA AND HERZEGOVINA* PHENAZOCINE 20 PHENOPERIDINE 10 COCAINE 1 000 PHOLCODINE 308 485 CODEINE 90C 000 PIRITRAMIDE 300 000 FENTANYL 100 RACEMETHORPHAN 20 METHADONE 1 000 SUFENTANIL 35 MORPHINE 1 500 THEBACON 41 692 PETHIDINE 3 000 THEBAINE 198 507 ,ILIDINE 1638 000 BOTSWANA BELIZE* CODEINE 400 DIHYDROCODEINE 2 000 COCAINE 100 DIPIPANONE 20 CODEINE 750 FENTANYL 5 ECGONINE 1 METHADONE 5 HEROIN 1 MORPHINE 1 000 !·lETHADONE 1 PETHIDINE E 000 SUFENTANIL 5 TILIDINE 100 PAGE 4 TOTAL OF ESTIMATES IN GRAM~ BRAZIL OPIUM 5 OC PETHIDINE 1 OC ALFENTA.1\1IL 480 PHOLCODINE 2 OC CODEINE 1020 000 DEXTROPROPOXYPHENE 700 000 CAMEROON DIPHENOXYLATE 250 000 FENTANYL 550 ALFENTANIL MORPHINE 1270 000 CODEINE 75 OPIUM 500 000 DEXTROMORAMIDE 14 PETHIDINE 350 000 ETHYLMORPHINE 2 Ol SUFENTAJ."JIL 3 FENTANYL 9 MORPHINE 1 70 BRITISH VIRGIN ISLANDS OPIUM 2 09 PETHIDINE 30 25 CODEINE 600 PHENOPERIDINE DIHYDROCODEINE 150 PHOLCODINE 8 25 DIPHENOXYLATE 12 MORPHINE 5 CANADA PETHIDINE 550 ALFENTANIL 72 BRUNEI :JARUSSALAM ALPHAPRODINE 20 ANILERIDINE 148 25 CODEINE 100 COCAINE 37 00 FENTANYL 3 CODEINE 17047 00 HEROIN 1 DEXTROPROPOXYPHENE 1314 00 METHADONE 1 DIFENOXIN MORPHINE 150 DIHYDROCODEINE PETHIDINE 1 100 DIHYDROMORPHINE DIPHENOXYLATE 21 21 BULGARIA ECGONINE ETHYLMORPHINE 10 ALFENTA.'HL 100 ETORPHINE COCAINE 20 000 FENTANYL 1 40 CODEINE 7150 000 HEROIN 2 23 DEXTROMORAMIDE 40 HYDROCODONE 81 55 DIHYDROCODEINE 30 000 HYDROMORPHONE 122 09 DIPHENOXYLATE 15 000 LEVORPHANOL 1 00 ETHYLMORPHINE 310 000 METHADONE 95 7" FENTANYL 170 METHYLCODEINE METHADONE 1 500 MORPHINE 1145 60 MORPHINE 300 000 MORPHINE-6-GLUCURONIDE OPIUM 880 000 MORPHINE-N-OXYDE PETHIDINE 100 000 NORCODEINE PIRITRA'1IDE 6 300 NORLEVORPHANOL SUFENTANIL 10 NORMETHADONE 91 60 TILIDINE 65 000 OPIUM
Recommended publications
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M

    INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M

    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
  • The Use of Nitrous Oxide Gas for Lower Gastrointestinal Endoscopy Sophie Welchman, Sean Cochrane, Gary Minto, Stephen Lewis

    The Use of Nitrous Oxide Gas for Lower Gastrointestinal Endoscopy Sophie Welchman, Sean Cochrane, Gary Minto, Stephen Lewis

    Systematic review: The use of nitrous oxide gas for lower gastrointestinal endoscopy Sophie Welchman, Sean Cochrane, Gary Minto, Stephen Lewis To cite this version: Sophie Welchman, Sean Cochrane, Gary Minto, Stephen Lewis. Systematic review: The use of nitrous oxide gas for lower gastrointestinal endoscopy. Alimentary Pharmacology and Therapeutics, Wiley, 2010, 32 (3), pp.324. 10.1111/j.1365-2036.2010.04359.x. hal-00552574 HAL Id: hal-00552574 https://hal.archives-ouvertes.fr/hal-00552574 Submitted on 6 Jan 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Alimentary Pharmacology & Therapeutic Systematic review: The use of nitrous oxide gas for lower gastrointestinal endoscopy ForJournal: Alimentary Peer Pharmacology Review & Therapeutics Manuscript ID: APT-0287-2010.R1 Manuscript Type: Systematic Review Date Submitted by the 13-May-2010 Author: Complete List of Authors: Welchman, Sophie; Derriford Hospital, Surgery Cochrane, Sean; Derriford Hospital, Gastroenterology Minto, Gary; Derriford Hospital, Anaesthesia Lewis, stephen; Derriford Hospital,
  • Federal Register/Vol. 85, No. 36/Monday, February 24, 2020

    Federal Register/Vol. 85, No. 36/Monday, February 24, 2020

    10466 Federal Register / Vol. 85, No. 36 / Monday, February 24, 2020 / Notices Controlled substance Drug code Schedule Alphamethadol ................................................................................................................................................................. 9605 I Benzethidine .................................................................................................................................................................... 9606 I Betacetylmethadol ........................................................................................................................................................... 9607 I Clonitazene ...................................................................................................................................................................... 9612 I Diampromide ................................................................................................................................................................... 9615 I Diethylthiambutene .......................................................................................................................................................... 9616 I Dimethylthiambutene ....................................................................................................................................................... 9619 I Ketobemidone .................................................................................................................................................................
  • 2020 Kansas Statutes

    2020 Kansas Statutes

    2020 Kansas Statutes 65-4105. Substances included in schedule I. (a) The controlled substances listed in this section are included in schedule I and the number set forth opposite each drug or substance is the DEA controlled substances code that has been assigned to it. (b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation: (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylacetamide) 9821 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide) 9815 (3) Acetylmethadol 9601 (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide; acryloylfentanyl) 9811 (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) 9551 (6) Allylprodine 9602 (7) Alphacetylmethadol 9603(except levo-alphacetylmethadol also known as levo- alpha-acetylmethadol, levomethadyl acetate or LAAM) (8) Alphameprodine 9604 (9) Alphamethadol 9605 (10) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine) 9814 (11) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- phenylpropanamide) 9832 (12) Benzethidine 9606 (13) Betacetylmethadol 9607 (14) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N- phenylpropanamide) 9830 (15) Beta-hydroxy-3-methylfentanyl (other
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )

    ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )

    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2019 (as of 10 January 2019 ) Afghanistan Cannabis 50 Codeine 50 000 Cannabis resin 1 Dextropropoxyphene 10 000 Coca leaf 1 Diphenoxylate 5 000 Cocaine 15 Fentanyl 1 Codeine 650 000 Methadone 20 000 Codeine -N-oxide 1 Morphine 8 000 Dextromoramide 1 Pethidine 90 000 Dextropropoxyphene 200 000 Pholcodine 40 000 Difenoxin 1 Albania Dihydrocodeine 1 Cocaine 1 Diphenoxylate 1 Codeine 1 189 000 Dipipanone 1 Fentanyl 300 Ecgonine 2 Heroin 1 Ethylmorphine 1 Methadone 7 000 Etorphine 1 Morphine 7 800 Fentanyl 17 000 Oxycodone 2 000 Heroin 1 Pethidine 2 700 Hydrocodone 10 000 Pholcodine 1 500 Hydromorphone 4 000 Remifentanil 9 Ketobemidone 1 Sufentanil 2 Levorphanol 1 Algeria Methadone 100 000 Alfentanil 350 Morphine 1 550 000 Codeine 2 500 000 Morphine -N-oxide 1 Etorphine 1 Nicomorphine 1 Fentanyl 500 Norcodeine 1 Methadone 4 000 Normethadone 1 Morphine 9 000 Normorphine 1 Oxycodone 4 000 Opium 10 Pethidine 3 000 Oripavine 1 Pholcodine 1 500 000 Oxycodone 60 000 Remifentanil 1 Oxymorphone 1 Sufentanil 30 Pethidine 50 000 Andorra Phenoperidine 1 Cannabis 2 000 Pholcodine 1 Fentanyl 100 Piritramide 1 Methadone 1 000 Remifentanil 20 000 Morphine 500 Sufentanil 10 Oxycodone 2 000 Thebacon 1 Pethidine 500 Thebaine 70 000 Remifentanil 4 Tilidine 1 Angola Armenia Alfentanil 20 Codeine 3 000 Codeine 21 600 Fentanyl 40 Dextromoramide 188 Methadone 13 500 Dextropropoxyphene 200 Morphine 7 500 Dihydrocodeine 500 Thebaine 15 Diphenoxylate 300 Trimeperidine 1 500 Fentanyl 63 Aruba* Methadone 2 000
  • Prescription Regulations Summary Chart Who Hold an Approval to Prescribe Methadone from Their

    Prescription Regulations Summary Chart Who Hold an Approval to Prescribe Methadone from Their

    Products included in the Triplicate Prescription Program* This is a reference list provided for convenience. While all generic medication names appear, only sample brand names are provided and it should not be viewed as an all-inclusive listing of all trade names of drugs included in the Triplicate Prescription Program. BUPRENORPHINE METHADONE BuTrans, Suboxone** Metadol, Methadose - May only be prescribed by physicians Prescription regulations summary chart who hold an approval to prescribe methadone from their BUTALBITAL PREPARATIONS provincial regulatory body*** Summary of federal and provincial laws governing prescription drug ordering, Fiorinal, Fiorinal C ¼ & C ½, Pronal, Ratio-Tecnal, records, prescription requirements, and refills Ratio-Tecnal C ¼ & C ½, Trianal, Trianal C ½ METHYLPHENIDATE Biphentin®, Foquest®, and Concerta® brands are excluded Revised 2019 BUTORPHANOL from TPP prescr ip t i o n p a d req u ir e m e n t s (generic versions Butorphanol NS, PMS-Butorphanol, Torbutrol (Vet), of these products require a triplicate presc ription) Torbugesic (Vet) Apo-Methyphenidate, PHL-Methylphenidate, PMS- Prescription regulations DEXTROPROPOXYPHENE Methylphenidate, PMS-Methylphenidate ER, Ratio- None identified Methylphenidate, Ritalin, Ritalin SR, Sandoz- According to the Standards of Practice for Pharmacists and Pharmacy Technicians: Methylphenidate SR, Teva-Methylphenidate ER-C FENTANYL/SUFENTANIL/ALFENTANIL 6.4 Neither a pharmacist nor a pharmacy technician may dispense a drug or blood product under a Alfentanil Injection,
  • A Review of Unique Opioids and Their Conversions

    A Review of Unique Opioids and Their Conversions

    A Review of Unique Opioids and Their Conversions Jacqueline Cleary, PharmD, BCACP Assistant Professor Albany College of Pharmacy and Health Sciences Adjunct Professor SAGE College of Nursing DISCLOSURES • Kaleo • Remitigate, LLC OBJECTIVES • Compare and contrast unique pharmacotherapy options for the treatment of chronic pain including: methadone, buprenoprhine, tapentadol, and tramadol • Select methadone, buprenorphine, tapentadol, or tramadol based on patient specific factors • Apply appropriate opioid conversion strategies to unique opioids • Understand opioid overdose risk surrounding opioid conversions and the use of unique opioids UNIQUE OPIOIDS METHADONE, BUPRENORPHINE, TRAMADOL, TAPENTADOL METHADONE My favorite drug because….? METHADONE- INDICATIONS • FDA labeled indications – (1) chronic pain (2) detoxification Oral soluble tablets for suspension NOT indicated for chronic pain treatment • Initial inpatient detoxification of opioids by a licensed trained provider with methadone and supportive care is appropriate • Methadone maintenance provider must have special credentialing and training as required by state Outpatient prescription must be for pain ONLY and say “for pain” on RX • Continuation of methadone maintenance from outside provider while patient is inpatient for another condition is appropriate http://cdn.atforum.com/wp-content/uploads/SAMHSA-2015-Guidelines-for-OTPs.pdf MECHANISM OF ACTION • Potent µ-opioid agonist • NMDA receptor antagonist • Norepinephrine reuptake inhibitor • Serotonin reuptake inhibitor ADVERSE EVENTS
  • Kappa Opioid Receptor Regulation of Erk1/2 Map Kinase Signaling Cascade

    Kappa Opioid Receptor Regulation of Erk1/2 Map Kinase Signaling Cascade

    1 KAPPA OPIOID RECEPTOR REGULATION OF ERK1/2 MAP KINASE SIGNALING CASCADE: MOLECULAR MECHANISMS MODULATING COCAINE REWARD A dissertation presented by Khampaseuth Rasakham to The Department of Psychology In partial fulfillment of the requirements for the degree of Doctor of Philosophy in the field of Psychology Northeastern University Boston, Massachusetts August, 2008 2 KAPPA OPIOID RECEPTOR REGULATION OF ERK1/2 MAP KINASE SIGNALING CASCADE: MOLECULAR MECHANISMS MODULATING COCAINE REWARD by Khampaseuth Rasakham ABSTRACT OF DISSERTATION Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Psychology in the Graduate School of Arts and Sciences of Northeastern University, August, 2008 3 ABSTRACT Activation of the Kappa Opioid Receptor (KOR) modulates dopamine (DA) signaling, and Extracellular Regulated Kinase (ERK) Mitogen-Activated Protein (MAP) kinase activity, thereby potentially regulating the rewarding effects of cocaine. The central hypothesis to be tested is that the time-and drug-dependent KOR-mediated regulation of ERK1/2 MAP kinase activity occurs via distinct molecular mechanisms, which in turn may determine the modulation (suppression or potentiation) by KOR effects on cocaine conditioned place preference (CPP). Three studies were performed to test this hypothesis. Study 1 examined the effects of U50,488 and salvinorin A on cocaine reward. In these studies, mice were treated with equianalgesic doses of agonist from 15 to 360 min prior to daily saline or cocaine place conditioning. At time points corresponding with peak biological activity, both agonists produced saline-conditioned place aversion and suppressed cocaine-CPP, effects blocked by the KOR antagonist nor-BNI. However, when mice were place conditioned with cocaine 90 min after agonist pretreatment, U50,488-pretreated mice demonstrated a 2.5-fold potentiation of cocaine-CPP, whereas salvinorin A-pretreated mice demonstrated normal cocaine-CPP responses.
  • Ketamine for Chronic Non- Cancer Pain: a Review of Clinical Effectiveness, Cost- Effectiveness, And

    Ketamine for Chronic Non- Cancer Pain: a Review of Clinical Effectiveness, Cost- Effectiveness, And

    CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Ketamine for Chronic Non- Cancer Pain: A Review of Clinical Effectiveness, Cost- Effectiveness, and Guidelines Service Line: Rapid Response Service Version: 1.0 Publication Date: May 28, 2020 Report Length: 28 Pages Authors: Khai Tran, Suzanne McCormack Cite As: Ketamine for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines. Ottawa: CADTH; 2020 May. (CADTH rapid response report: summary with critical appraisal) ISSN: 1922-8147 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document.
  • Best Bets from the Manchester Royal Infirmary Edited by K Mackway-Jones

    Best Bets from the Manchester Royal Infirmary Edited by K Mackway-Jones

    247 BEST EVIDENCE TOPIC REPORTS Emerg Med J: first published as 10.1136/emj.19.3.248 on 1 May 2002. Downloaded from Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary Edited by K Mackway-Jones Clinical scenario Best evidence topic reports (BETs) summarise the evidence A 23 year old woman attends an emergency department hav- pertaining to particular clinical questions. They are not ing taken sixty 500 mg paracetamol tablets. Her four hour systematic reviews, but rather contain the best (highest paracetamol levels are above the treatment line. She does not level) evidence that can be practically obtained by busy want to be treated with intravenous therapy. You wonder practising clinicians. The search strategies used to find the whether oral antidote is as effective. best evidence are reported in detail in order to allow clinicians to update searches whenever necessary. The BETs published below were first reported at the Critical Three part question Appraisal Journal Club at the Manchester Royal Infirmary.1 In [patients who need an antidote for paracetamol overdose] Each BET has been constructed in the four stages that have is [intravenous therapy better than oral therapy] at [prevent- been described elsewhere.2 The BETs shown here together ing liver damage and death]? with those published previously and those currently under construction can be seen at http://www.bestbets.org.3 Six Search strategy BETs are included in this issue of the journal. Medline 1966 to 12/01 using the OVID interface. [exp acetyl-
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens

    Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens

    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.